Testing a new injection to prevent bleeding in severe clotting disorders

This trial is testing whether emicizumab, a medication that works differently than current treatments, can safely prevent bleeding in patients with severe von Willebrand disease or von Willebrand disease combined with hemophilia A. Unlike existing treatments that require intravenous infusions, this medication is given as a subcutaneous injection (under the skin), which may be easier and more convenient for patients to use regularly.

Patients with severe bleeding disorders like von Willebrand disease currently depend on intravenous treatments that can be inconvenient and difficult to use for long-term prevention of bleeding. This study explores whether this medication could offer a simpler, easier-to-use option for preventing bleeding episodes.